A5071911013- Immune cells in cancer
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Metabolomics and Mass Spectrometry Studies
- Ferroptosis and cancer prognosis
- Autophagy in Disease and Therapy
- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Melanoma and MAPK Pathways
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Research and Treatments
- CAR-T cell therapy research
- Endoplasmic Reticulum Stress and Disease
- Multiple Myeloma Research and Treatments
IRCCS Humanitas Research Hospital
2021-2025
Humanitas University
2021-2024
Candiolo Cancer Institute
2022
Istituti di Ricovero e Cura a Carattere Scientifico
2022
Tumor-associated macrophages (TAMs) are correlated with the progression of prostatic adenocarcinoma (PCa). The mechanistic basis this correlation and therapeutic strategies to target TAMs in PCa remain poorly defined. Here, single-cell RNA sequencing was used profile transcriptional landscape human PCa, leading identification a subset characterized by dysregulation pathways associated lipid metabolism. This correlates positively shorter disease-free survival is an accumulation lipids that...
842 Background: Advanced Bladder Cancer (BC) presents significant challenges due to its high incidence and limited treatment options. Most patients initially present with non-muscle invasive bladder cancer (NMIBC), managed transurethral resection (TURBT) Bacillus Calmette–Guerin (BCG) therapy. However, some cancers recur or develop resistance, progressing muscle-invasive (MIBC), which is associated mortality curative While radical cystectomy (RC) the standard for MIBC, it has considerable...
NK cells are endowed with tumor killing ability, nevertheless most cancers impair cell functionality, and cell-based therapies have limited efficacy in solid tumors. How render dysfunctional is unclear, overcoming resistance an important immune-therapeutic aim. Here, we identify autophagy as a central regulator of anti-tumor function. Analysis differentially expressed genes tumor-infiltrating versus non-tumor from our previously published scRNA-seq data advanced human prostate cancer shows...
BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E protein targeted through the use of inhibitors which are approved for treatment melanoma; however, their long-term efficacy hampered by resistance mechanisms. The PROTAC-induced degradation has been proposed as an alternative strategy to avoid onset resistance. In this study, we designed series compounds where inhibitor encorafenib was conjugated pomalidomide different linkers. synthesized maintained ability...
Serine/threonine‐protein kinase B‐raf ( BRAF ) mutations are found in 8–15% of colorectal cancer patients and identify a subset tumors with poor outcome the metastatic setting. We have previously reported that BRAF‐ mutant human cells display high rate protein production, causing proteotoxic stress, selectively sensitive to proteasome inhibitors bortezomib carfilzomib. In this work, we tested whether carfilzomib could restrain growth not only by targeting directly, but also promoting an...
You have accessJournal of UrologyCME1 Apr 2023MP14-11 SINGLE CELL-BASED IMMUNE PROFILING OF THE TUMOR AND ITS MICROENVIRONMENT REVEALED DIFFERENCES BETWEEN NMIBC MIBC: IMPLICATION FOR IMMUNO-THERAPY Massimo Lazzeri, NicolòMaria Buffi, Giovanni Lughezzani, Paolo Casale, Roberto Hurle, Alberto Saita, Vittorio Fasulo, Marco Paciotti, Marta Pandini, Roberta Carriero, Mattia Carvetta, Iovino, Piergiuseppe Colombo, Grazia Elefante, Gianluca Basso, Sergio Marchini, Kunderfranco, and Diletta Di...